Scilex Holding Co (Scilex Holding Co) EBIT per Share : $-0.89 (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Scilex Holding Co EBIT per Share?

Scilex Holding Co's EBIT per Share for the three months ended in Mar. 2024 was $-0.23. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.89.

During the past 3 years, the average EBIT per Share Growth Rate was -45.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Scilex Holding Co's EBIT per Share or its related term are showing as below:

SCLX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -45.1 Med: -8.2 Max: 28.7
Current: -45.1

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Scilex Holding Co was 28.70% per year. The lowest was -45.10% per year. And the median was -8.20% per year.

SCLX's 3-Year EBIT Growth Rate is ranked worse than
93.4% of 863 companies
in the Drug Manufacturers industry
Industry Median: 7.3 vs SCLX: -45.10

Scilex Holding Co's EBIT for the three months ended in Mar. 2024 was $-23.85 Mil.

Scilex Holding Co EBIT per Share Historical Data

The historical data trend for Scilex Holding Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scilex Holding Co EBIT per Share Chart

Scilex Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-1.22

-0.26

-0.37

-0.10

-0.87

Scilex Holding Co Quarterly Data
	Dec19	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial							-0.18	-0.19	-0.25	-0.22	-0.23

Scilex Holding Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Scilex Holding Co's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-113.25	/	130.298
=	-0.87

Scilex Holding Co's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-23.846	/	102.407
=	-0.23

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.89

Scilex Holding Co (NAS:SCLX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Scilex Holding Co EBIT per Share Related Terms

Thank you for viewing the detailed overview of Scilex Holding Co's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Scilex Holding Co (Scilex Holding Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

960 San Antonio Road, Palo Alto, CA, USA, 94303

Website

https://www.scilexholding.com

Scilex Holding Co is engaged in the development and commercialization of non-opioid pain management products. The company's lead product ZTlido.

Executives

Sclx Stock Acquisition Jv Llc	10 percent owner	960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Jay Chun	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Yue Alexander Wu	director	C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Stephen Hoi Ma	officer: Chief Financial Officer	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Tien-li Lee	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sorrento Therapeutics, Inc.	10 percent owner	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
David Lemus	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Dorman Followwill	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Henry Ji	director, officer: Executive Chairperson	5370 RUETTE DE MER, SAN DIEGO CA 92130
Jaisim Shah	director, officer: See Remarks	C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Elizabeth Czerepak	officer: See Remarks	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Suneel G Kaji	director	25/28 OLD BURLINGTON STREET, LONDON X0 W1S 3AN
Steve Myint	director	C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632